TXG Nov 2024 30.000 call
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 30.00 |
| Expiry date | 2024-11-15 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR Newswire10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation and industry-leading speed and throughput.
Simply Wall St.We Think Some Shareholders May Hesitate To Increase 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation
Key Insights 10x Genomics to hold its Annual General Meeting on 11th of June Total pay for CEO Serge Saxonov includes...
- PR Newswire
10x Genomics Launches 5,000-Plex Gene Panel for Xenium
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.
